key: cord-0966713-r6h82ahz
authors: Gilchuk, Pavlo; Thomsen, Isaac; Yoder, Sandra; Brady, Eric; Chappell, James D.; Stevens, Laura J.; Denison, Mark R.; Sutton, Rachel E.; Chen, Rita E.; VanBlargan, Laura A.; Suryadevara, Naveen; Zost, Seth J.; Schmitz, Jonathan; Pulley, Jill M.; Diamond, Michael S.; Rhoads, Jillian P.; Bernard, Gordon R.; Self, Wesley H.; Rice, Todd W.; Wheeler, Allison P.; Crowe, James E.; Carnahan, Robert H.
title: Standardized two-step testing of antibody activity in COVID-19 convalescent plasma
date: 2021-12-08
journal: iScience
DOI: 10.1016/j.isci.2021.103602
sha: 691fb4f3a4af5396a4b34d26469ab2e9edddcd89
doc_id: 966713
cord_uid: r6h82ahz

The COVID-19 pandemic revealed an urgent need for rapid profiling of neutralizing antibody responses and development of antibody therapeutics. The current Food and Drug Administration-approved serological tests do not measure antibody-mediated viral neutralization, and there is a need for standardized quantitative neutralization assays. We report a high-throughput two-step profiling approach for identifying neutralizing convalescent plasma. Screening and down-selection for serum antibody binding to the receptor-binding domain are followed by quantitative neutralization testing using a chimeric vesicular stomatitis virus expressing spike protein of SARS-CoV-2 in a real-time cell analysis assay. This approach enables a predictive screening process for identifying plasma units that neutralize SARS-CoV-2. To calibrate antibody neutralizing activity in serum from convalescent plasma donors, we introduce a neutralizing antibody standard reagent composed of two human antibodies that neutralize SARS-CoV strains, including SARS-CoV-2 variants of concern. Our results provide a framework for establishing a standardized assessment of antibody-based interventions against COVID-19.

Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 64 as a major threat to global public health, many studies have focused efforts on identifying and 65 evaluating antibody-based therapeutic interventions (Baum et al., 2020; Chen et al., 2021b; Jones 66 et al., 2021; Liu et al., 2020; Robbiani et al., 2020; Rogers et al., 2020; Taylor et al., 2021; Zost et 67 al., 2020a) . Neutralizing antibodies to the spike (S) protein of SARS-CoV-2 elicited during 68 naturally occurring infection, or vaccination are considered a serological correlate of protection 69 (Corbett et al., 2021; Krammer, 2021) . Amongst the most low-cost and easily accessible sources 70 of human antiviral antibodies are plasma from SARS-CoV-2 convalescent donors to treat infection 71 in high-risk patients. Accordingly, numerous large-scale randomized, controlled trials are ongoing 72 to determine if COVID-19 convalescent plasma is a safe and effective treatment for 73 and the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) in 74

August of 2020 for passive transfer of COVID-19 convalescent plasma for treatment of COVID-75 19 (FDA, 2020) . Establishing antibody binding and neutralizing titers for convalescent plasma 76 correlated with protection would be significant for public health considerations and patient 77 management. However, the current FDA-approved serological tests for screening activity in serum 78 samples from convalescent plasma donors do not specifically measure antibody-mediated viral 79 neutralization (FDA, 2021b) , and relatively few studies have attempted a systematic analysis to 80 correlate quantitative antibody binding results with neutralization results in serum or plasma. In 81 addition, the lack of standardized laboratory neutralization assays and potency standards 82 (Gundlapalli et al., 2021; Khoury et al., 2020) hinders the evaluation and use of convalescent 83 plasma both within and across these large-scale studies. 84

This study describes a systematic evaluation of antibody reactivity and neutralization in a 85 large set of human convalescent plasma units designated for transfusion in the Passive Immunity 86

Trial for Our Nation (PassITON) (Self et al., 2021) using currently available clinical-use and newly 87 developed laboratory methodologies. To harmonize the results from different studies and calibrate 88 neutralizing activity in convalescent plasma, we propose a GMP-grade immunoglobulin standard 89 composed of two recombinant human mAbs that broadly neutralize SARS-CoV-2 strains, 90 including variants of concern. Our data provide a framework for standardized assessment of studies. RTCA has demonstrated high performance with representative strains from several virus 102 families and offers potential advantages over conventional laboratory plaque or focus reduction 103 neutralization tests (PRNT or FRNT) (Gilchuk et al., 2020a; Gilchuk et al., 2020b; Zost et al., 104 2020b) . RTCA provides a continuous automated measurement of cellular impedance in a 6 x 96-105 well plate format using an xCELLigence RTCA MP Analyzer (Agilent Technologies) instrument 106 to quantify virus-induced cytopathic effect (CPE) in virus-infected cell culture monolayers. We 107 recently deployed RTCA-based assays using Vero cells in a BSL3 environment (using authentic 108 SARS-CoV-2 live virus suspensions) or in a BSL2 environment (using chimeric vesicular 109 stomatitis virus [VSV] expressing SARS-CoV-2 S protein) for large-scale discovery of human 110 monoclonal antibodies (mAbs) that neutralize SARS-CoV-2 (Suryadevara et al., 2021; Zost et al., 111 2020b) . We also described the application of RTCA to measure antibody-mediated neutralizing 112 activity in serum from an individual after vaccination with mRNA-encoded spike protein (Chen et 113 al., 2021a) . Overall, these prior studies suggested this automated CPE measurement approach for 114 quantitative and high-throughput antibody screening might be of utility for serological screening. 115

We assessed the performance, precision, and reproducibility of RTCA for neutralizing 116 antibody testing in serum, which serves as a proxy for antibody levels and neutralizing activity in 117 J o u r n a l P r e -p r o o f contemporaneously collected plasma. For our workflow, we used a replication-competent chimeric 118 VSV expressing the S protein from SARS-CoV-2 (WA1/2020 strain) (Case et al., 2020b) . The 119 ability of this fully infectious virus to induce rapid CPE allows for high-throughput and 120 quantitative neutralization assessment in a BSL2 laboratory. 121

Serum is a complex biological matrix that may differentially impact measurements of 122 antibody neutralization by different assays. To assess if the RTCA assay could reliably measure 123 neutralizing activity of an antibody in the context of human serum, we used the previously 124 developed potently neutralizing mAb COV2-2196 (Zost et al., 2020a) or a combination of two 125 potently neutralizing human mAbs COV2-2130 and COV2-2381 (Zost et al., 2020a ) that form a 126 basis of investigational drug product against COVID-19 designated ADM03820 127 (ClinicalTrials.gov Identifier: NCT04592549). Purified neutralizing mAbs carried in normal 128 human serum or cell culture growth medium showed equivalent performance in measuring 129 antibody neutralization in the RTCA assay ( Figure 1A) . 130

To define quantitative measurements of antibody neutralizing activity in serum, we 131 assembled a training set of 76 SARS-CoV-2 serum samples from individuals who had recovered 132 from COVID-19. This panel represented individuals with a broad spectrum of clinical severity 133 from severe disease (n=6) to mild to moderate disease (n=63), a wide range of ages (20 to 70 134 years), and a balance of sexes (54.3% female / 44.3% male / 1.4% unknown) ( Table S1) . Serially 135 diluted serum samples neutralized VSV-SARS-CoV-2 in a dose-dependent manner. This analysis 136 identified 6 samples with high (>95% virus neutralization at the lowest tested [1:50] serum 137 dilution), 11 samples with medium (50 to 90%), and 59 samples with low (<50%) neutralizing 138 activity ( Figure 1B) . Determination of half-maximal neutralization titer (NT50) or neutralization 139 titer that reduced virus infectivity by 80% (NT80) provided a quantitative assessment of samples 140 J o u r n a l P r e -p r o o f exhibiting high or moderate neutralizing activity. Area under the curve (AUC) assessment allowed 141 for potency ranking across the entire sample set, including serum with low neutralizing activity. 142

To assess assay precision and reproducibility, we analyzed the full set of 76 samples from 143 two independent experiments, using the mean of duplicate measurements for each experiment. 144

Orthogonal regression showed excellent agreement (1.000*X + 0.0736; P<0.0001) (Figure 1C) . 145

The Bland-Altman plot showed little difference between repeated measurements, although the 146 variability of AUC measurements was higher for samples exhibiting low neutralizing activity 147 (log10AUC<3.5 with the limit of detection [LOD] =2.7) ( Figure 1D ). Serum samples that exhibited 148 NT50 values ≥ 50 showed strong agreement (0.9364*X + 0.4147; P<0.0001) ( Figure 1E ) and low 149 variability (bias=0.1990; 95% limits of agreement from -2.57% to 2.97% difference) ( Figure 1F ) 150 between the two independent experiments. This highlights the high assay accuracy and 151 reproducibility in quantifying high to moderate levels of neutralizing activity in potentially 152 clinically relevant samples. 153

In summary, our results demonstrated high performance of RTCA methodology in a BSL2 154 laboratory setting for quantitative neutralizing antibody assessment in human serum. 155 156

We next defined a workflow for evaluating anti-SARS-CoV-2 antibody response by 158 performing a multifactorial assessment of antibody features in serum samples. For benchmarking 159 purposes, we used 76 SARS-CoV-2 serum samples from individuals who had recovered from 160 COVID-19 infections ( Figure 1B ; Table S1 ). We carried out three quantitative or semi-161 quantitative assays to understand the relationship between these assay measurements in 162 convalescent plasma evaluation: 1) antibody binding to SARS-CoV-2 S protein, 2) inhibition of 163 J o u r n a l P r e -p r o o f SARS-CoV-2 spike RBD (SRBD) binding to human angiotensin-converting enzyme 2 (ACE2) 164 receptor protein, or 3) virus neutralization. 165 Antibody binding was assessed by two commercial automated clinical-use tests that carry 166 an EUA from the FDA: (1) Ortho VITROS Anti-SARS-CoV-2 IgG (S protein binding, semi-167 quantitative assay) (FDA, 2021d), and (2) Abbott AdviseDx II SARS-CoV-2 IgG (SRBD protein 168 binding; quantitative assay) (FDA, 2021a) (see Methods). We also tested other antibody binding 169 assays, including an automated research-use assay, Leinco Trace IgG micro-ELISA (Leinco 170

Technologies, semi-quantitative assay), and a recently reported high-throughput fluorescence-171 based quantitative binding assay using MagPlex microspheres (Bennett et al., 2021) , both of which 172 measure IgG binding to the SRBD. Additionally, we evaluated a bead-based ACE2-inhibition semi-173 quantitative assay (Leinco Technologies) that measures the ability of an antibody-containing 174 sample to inhibit the interaction of recombinant SRBD with the recombinant extracellular domain 175 of human ACE2 and, therefore, is considered a surrogate measurement of antibody neutralization. 176

We first evaluated the relationship between antibody binding and neutralization. 177

Measurements from each binding assay for individual serum samples were compared to their 178 respective AUC measurements estimated from the dose-response RTCA assay neutralization 179 curves ( Figure 1A) . The analysis revealed a relationship between antibody binding and 180 neutralization suggestive of a binding threshold below which samples did not exhibit detectable 181 neutralizing activity based on half-maximal neutralization titer measurement (i.e., samples with 182 NT50 ≥ 50 indicated with violet dots in Figure 2) . Moreover, samples with relatively high binding 183 activity measured by each assay varied from high to low neutralizing activity. Better agreement 184 was observed between RTCA assay neutralizing activity and ACE2 inhibition assay 185 measurements, consistent with previous studies that demonstrated a significant fraction of 186 J o u r n a l P r e -p r o o f neutralizing antibodies in serum or isolated mAbs inhibit ACE2 binding to the SRBD (Liu et al., 187 2020; Robbiani et al., 2020; Zost et al., 2020b) . We conclude that high antibody binding titers to 188 SARS-CoV-2 antigens are required for virus neutralization but do not fully predict the level of 189 neutralizing activity in serum. 190

As the key measure of antibody-antigen binding in this study, we implemented a 191 fluorescent SARS-CoV-2 RBD-coupled MagPlex microsphere binding assay (Bennett et al., 2021) 192 (defined as RBD-binding fluorescent assay). This microsphere fluorescence-based assay has 193 advantages for convalescent plasma testing in a research laboratory setting due to high throughput, 194 wide dynamic range, and high accuracy compared to ELISA binding assays. In addition, this assay 195 measures antibody binding to SRBD, the principal target for anti-SARS-CoV-2 neutralizing 196 antibodies. A comparison of the RBD-binding fluorescent assay to the other binding assays 197 measurements using the same set of 76 samples identified the majority of 17 top neutralizing 198 samples (NT50 ≥ 50; Figure 1D ) within the category of moderate-to-high binding activity for each 199 assay ( Figure 2B ). These results demonstrated better performance by the RBD-binding fluorescent 200 assay relative to the semi-quantitative commercial SARS-CoV-2 antigen-binding assays in its 201 ability to eliminate a large fraction of samples with low neutralizing activity and narrow the focus 202 to samples that are most likely to have medically relevant levels of neutralizing antibodies. 203 Importantly, RBD-binding fluorescent assay measurements revealed excellent agreement with the 204 quantitative FDA-approved Abbott AdviseDx II assay (Y = 1.092*X+0.9307; P<0.001), which 205 measures binding to SRBD. Both assays reliably identified 17 samples with RTCA NT50 ≥ 50 within 206 the category of high binders ( Figure 2B) . 207

Plasma transfusions immediately followed serum testing and transfusion unit down-208 selection, and, therefore, serum testing was performed in small batches and based on plasma 209 availability collected from donors. For these reasons, the thresholds for RBD binding (≥8,000 210 EU/mL) and neutralizing (NT50≥ 50) activities in our two-step screening approach were selected 211 empirically from the limited data available to allow a sufficient fraction of convalescent plasma 212 samples to be used for transfusions (17 of 76 or ~22% of the original units would have met this 213 criterion). 214

A large-scale comparison of RTCA and RBD-binding fluorescent assays carried out using 215 226 serum samples (Table S1) further supported our findings that beyond an empirically defined 216 threshold for antibody-antigen binding (8,000 EU/mL), above which most neutralizing samples 217 were found (NT50≥ 50), no further discrimination of antibody neutralization potency could be 218 inferred from binding data ( Figure 2C-D) . Samples with an antibody binding level above 8,000 219 EU/mL in the RBD-binding fluorescent assay and half-maximal neutralization titer ≥ 50 were 220 selected for transfusion in the PassITON trial (Self et al., 2021) . The sensitivity and specificity to 221 detect neutralizing activity above pre-specified binding threshold was 64% and 93%, respectively 222 as detailed in the Methods. 223

In summary, these results revealed a discrepancy between binding activity and 224 neutralization activity that highlights the importance of directly assessing neutralizing potency of 225 antibody-containing samples. Our results suggested a threshold level of RBD-binding activity in 226 the RBD-binding fluorescent assay (8,000 EU/mL of serum) correlated with reproducible 227 detection of neutralizing activity (RTCA NT50 ≥ 50; Figure 2D ). Together these studies offered a 228 streamlined workflow for accurate profiling of SARS-CoV-2 binding and neutralizing activity of 229 human serum under BSL2 conditions via a sequential algorithm consisting of screening by RBD-230 binding fluorescent assay followed by potency quantification using RTCA assay (Figure 3) . Numerous in vitro assays assessing the neutralizing activity of anti-SARS-CoV-2 235 antibodies have been reported (Khoury et al., 2020) . The plaque reduction neutralization test 236 (PRNT) using live SARS-CoV-2 in BSL3 containment was widely employed for monoclonal and 237 polyclonal antibody neutralization assessment, including profiling of neutralizing antibody 238 responses in serum of SARS-CoV-2 mRNA vaccines in clinical trials (Anderson et al., 2020; 239 Jackson et al., 2020) . Several factors, including the density of spike protein on the virion, geometry 240 of viral particle, replication kinetics, and differences in parental virus (VSV) proteins, can 241 potentially affect the mechanics of cell entry and the ability of antibodies to neutralize chimeric 242 infectious VSV-SARS-CoV-2 relative to native SARS-CoV2 (Case et al., 2020b) . In addition, 243 there are inherent differences between PRNT and CPE-based RTCA assays in how these assays 244 measure the level of infection at the endpoint. Therefore, we next determined the relationship 245 between quantitative measurements from the VSV-SARS-CoV-2 RTCA and authentic SARS-246

CoV-2 PRNT assays by comparing neutralizing antibody titers in serum. 247

From the 76-sample training set described in Figure 2A , ten samples representing a broad 248 range of neutralizing activity by RTCA were selected ( Figure 4A ). Nine of these ten samples had 249 RBD-binding activity above the suggested RBD-binding fluorescent assay threshold level (≥ 8,000 250 EU/mL of serum) but varying neutralization levels from high to below the limit of detection (1:50 251 was the lowest tested serum dilution). One sample had low binding and low neutralizing activities 252 (sample 10) and was used as a control. Of note, this panel of 10 included samples that showed 253 similar and high binding to RBD but varying neutralization levels (e.g., samples 3, 5, 7, and 9). 254

We performed parallel RTCA and PRNT assays with these samples using a broader range 255 of serum dilutions. Estimated NT50 and NT80 values from the dose-response neutralization curves 256 demonstrated strong agreement between RTCA and PRNT assays. Additionally, all ten samples 257 ranked similarly by neutralization results in both assays (Figure 4B-E) . A noticeable difference 258 was observed between the slopes of the curves, with RTCA assay curve slopes being considerably 259 "steeper" than those observed by PRNT (Figure 4D, E) . We speculate that this result might be 260 explained by inherent differences between the endpoint measurements in these two assays; e.g., 261

PRNT reflects the fractional reduction in the number of plaque-forming units in the initial 262 inoculum, while CPE quantification relies on endpoint measurement after multiple cycles of virus 263 release and entry. Nevertheless, a high agreement was observed for the NT80 values determined 264 from the PRNT and RTCA dose-response curves for all ten tested samples. Given that PRNT-265 estimated NT80 values were used in previous studies as a measure for serum neutralizing activity 266 in clinical trials that tested the efficacy of COVID-19 mRNA vaccines (Anderson et al., 2020; 267 Jackson et al., 2020) , this finding supports RTCA NT80 estimation as a predictor of antibody 268 neutralizing potency against authentic SARS-CoV-2. Together, these results demonstrate that the 269 VSV-SARS-CoV-2 RTCA assay performed similarly to authentic SARS-CoV-2 PRNT assay for 270 quantitative assessment and potency ranking of convalescent serum neutralization. 271 272

composed of two human mAbs that broadly neutralize SARS CoV-2 strains, including 274 variants of concern. 275 Quantitative standardization of COVID-19 convalescent plasma or antibody-based 276 interventions testing is critical for comparing the results across different studies (Gundlapalli et 277 al., 2021) . However, standardization methods for neutralization testing, especially CPE-based 278 assays, have limitations. These limitations include variation in operator performance, differences 279 in implementation across laboratories, and the potential for lack of consistency over time as new 280 virus stocks and/or cell culture stocks and/or cell lines are used. Using a biological standard 281 antibody solution with defined neutralizing activity would allow for calibration and harmonization 282 of the data from different studies and laboratories, as has been done in the past for the other viruses 283 (Mattiuzz et al., 2019) . We developed such an approach to calibrate serum antibody binding 284 activity in two commercial automated clinical-use tests that carry an EUA from the FDA. 285

For neutralization testing assays, we initially implemented the First WHO International 286

Standard for anti-SARS-CoV-2 immunoglobulin (defined as "WHO Standard" for simplicity). 287

This standard is composed of pooled plasma obtained from eleven individuals recovered from 288 SARS-CoV-2 infection. This WHO Standard was developed and evaluated to calibrate and 289 harmonize serological assays detecting anti-SARS-CoV-2 neutralizing antibodies by WHO 290

International Collaborative study (Mattiuzzo et al., 2020) . The assigned potency of the WHO 291

Standard for SARS-CoV-2 is 1,000 International Units (IU)/mL for neutralizing antibody activity 292 against the WA1/2020 strain of SARS-CoV-2. Several factors, however, limit the utility of the 293 WHO Standard for worldwide applications in the current pandemic scenario: (1) the limited supply 294 of WHO Standard preparations; (2) the challenging requirement for repeated plasma collection 295 from the same or other individuals to match the assigned biological potency and replenish current 296 stocks of the standard; and (3) considerable variation of neutralizing activity against circulating 297 SARS-CoV-2 variants of concern in human plasma collected from different individuals (Chen et 298 al., 2021c; Wang et al., 2021) . These findings suggest that testing of convalescent plasma using a 299 standard plasma reagent calibrated only against historical SARS-CoV-2 strains is no longer 300 advisable. 301

Two potently neutralizing human mAbs COV2-2130 and COV2-2381, targeting non-302 overlapping epitopes on the RBD of the SARS-CoV-2 spike protein (Zost et al., 2020a) , form the 303 basis of the investigational drug product ADM03820 against COVID-19 (ClinicalTrials.gov 304 Identifier: NCT04592549). Given a virtually unlimited supply of these antibodies and their high 305 potency in SARS-CoV-2 neutralization, we used a GMP-grade formulation of ADM03820 as the 306 immunoglobulin standard for calibration of neutralizing antibody activity in convalescent serum. 307

First, we assessed neutralization by WHO Standard or ADM03820 formulations across a range of 308 plasma dilutions or mAb concentrations ( Figure 5A , B). The activity of ADM03826 was 309 expressed as IU/mg of IgG protein, and it was calculated using NT80 values estimated from dose-310 response curves for the WHO Standard and ADM03826. The potency observed using 1,000 IU/mL 311 of the WHO Standard reagent corresponded to that afforded by a 14.8 g/mL IgG concentration 312 of ADM03826. Because our convalescent serum evaluation workflow involves sequential RBD 313 binding + RTCA neutralization testing, we next demonstrated the utility of ADM03826 for 314 calibration of antibody RBD binding against the WHO Standard using the RBD-binding 315 fluorescent assay ( Figure 5C, D) . 316

Next, we quantified neutralizing antibody activity in 76 serum samples (described in 317

Figures 1, 2) by performing a separate RTCA assay in which ADM03826 was used as an internal 318

reference. Serum samples were tested across a broad range of dilutions along with ADM03826. 319

Only 40 of 76 samples exhibited neutralizing potency that allowed for NT80 estimation (1:25 was 320 the lowest tested serum dilution). These results demonstrated that the activity in these neutralizing 321 sera ranged from 150 to 2,680 IU/mL ( Figure 5E ). In addition, a large fraction of these 40 samples 322 exhibited considerably lower activity relative to WHO Standard, highlighting that most of the 323 samples in the panel are unlikely to be clinically useful due to the low neutralizing antibody titers 324 observed. 325

Finally, in parallel, we performed focus reduction neutralization test (FRNT) assays in a 326 BSL3 laboratory with WHO Standard and ADM03826 using parental strain WA1/2020 SARS-327

CoV-2, SARS-CoV-2 WA1/2020 bearing a D614G mutation, authentic B. (Chen et al., 2021c) . 330

The WHO Standard neutralizing titer was relatively low, with full neutralization of tested viruses 331 achieved only at the 1:50 to 1:100 dilutions of the Standard plasma reagent ( Figure 6A ). In 332 contrast, ADM03826 fully neutralized the viruses at relatively low antibody concentrations 333 (greater than 120 ng/mL), demonstrating a much higher neutralizing potency for the ADM03826 334 values. ADM03826 neutralized all tested viruses with similar high potency (IC80 ranged from 37 338 to 58 ng/mL) except for even greater potency against Wash-B.1.1.28 (NT80 = 16) ( Figure 6C) . 339

Together, these studies showed broad neutralizing activity mediated by ADM03826 340 against SARS-CoV-2 variants of concern and demonstrated the utility of ADM03826 for the 341 standardization and calibration of serological antibody neutralization assays. This study describes an optimized approach and methodology for selecting convalescent 345 plasma for clinical use based on neutralizing antibody functionality. We demonstrated that 346 antiviral activity could not be assessed adequately with antibody binding assays alone due to a 347 complex relationship between antibody binding and virus neutralization. The studies reveal that 348 antibody-mediated antiviral activity is best evaluated through a combination of both antigen 349 binding and virus neutralization assays. In addition, we developed a universal neutralizing 350 antibody standard that can be manufactured reproducibly, and that is aligned to the WHO anti-351 SARS-CoV-2 immunoglobulin standard for use as a calibrator to ensure reproducibility of 352 serological antibody neutralization assays. (FDA, 2021c) as an acceptable test for use in the manufacture of high titer COVID-19 convalescent 368 plasma. Notably, while many SARS-CoV-2 elicited antibodies bind the spike protein, only a subset 369 of binding antibodies confers antiviral neutralization (Liu et al., 2020; Robbiani et al., 2020; 370 Rogers et al., 2020; Zost et al., 2020b) , which is highly predictive of immune protection (Khoury 371 et al., 2021) . Another EUA methodology is based on inhibition of RBD binding to the human 372 ACE2 receptor, and this test has been suggested to be a surrogate of neutralization testing 373 (Laboratory Corporation of America, 2020). However, the application of this assay for inferring 374 SARS-CoV-2 neutralization by plasma antibodies is limited. Recent studies revealed that prevalent 375 neutralizing plasma antibody responses in some individuals are directed against the N-terminal 376 domain (NTD) of the SARS-CoV-2 spike protein, which lies outside of the RBD (Voss et al., 377 2021) ; however, these neutralizing antibodies do not inhibit binding to ACE2 (Chi et al., 2020; 378 McCallum et al., 2021; Suryadevara et al., 2021) . In addition, several RBD-specific antibodies 379 have been described that neutralize SARS-CoV-2 but do not block ACE2 binding, including S309, 380 an antibody in clinical use (Pinto et al., 2020) . The initial RBD binding screening in the two-step 381 plasma profiling approach allows pre-selection of samples most likely to exhibit high neutralizing 382 activity based on our observation of a threshold effect, where samples with NT50 ≥ 50 all had high 383 RBD binding. Notably, preliminary analyses with either 76 or 226 samples not pre-selected based 384 on binding supported the utility of pre-screening based on RBD binding, as we were unable to 385 observe neutralization in samples with RBD binding below the observed threshold. The second 386 step then involves a neutralization screen that measures overall activity by all classes of 387 neutralizing antibodies, unlike an ACE2 inhibition assay where performance is limited to detecting 388 neutralizing activity against RBD. 389 Several studies have demonstrated the utility of IgG binding assays for predicting SARS-390

CoV-2 neutralizing activity in COVID-19 plasma (Boonyaratanakornkit et al., 2021; Legros et al., 391 2021) . However, several lines of evidence highlight the necessity of direct virus neutralization 392 testing for assessment of the protective capacity of convalescent plasma: (1) a complex relationship 393 between binding and neutralization titers against SARS-CoV-2 in convalescent plasma that varies 394 depending on the clinical assay used and the cohort studied ( (Chia et al., 2021; Gniadek et al., 395 2021; Grzelak et al., 2020; Muecksch et al., 2021; Rathe et al., 2021) ; this study)); (2) limited 396 suitability of commercial serological assays for inferring neutralizing activity against SARS-CoV-397 2 in convalescent plasma ((Tang et al., 2020; Valdivia et al., 2021) ; this study)); (3) transfusion of 398 convalescent plasma with low neutralizing titers predictably did not increase recipient plasma 399 neutralizing activity (Bradfute et al., 2020) ; and (4) several studies have reported accelerated viral 400 evolution and the emergence of viruses with mutations in persistently infected 401 immunocompromised individuals treated with convalescent plasma (Choi et al., 2020; Kemp et 402 al., 2021; McCarthy et al., 2021) , prompting consideration that transfusion of convalescent plasma 403 with a high-titer of binding antibodies but low or sub-optimal neutralizing activity may have 404 adverse consequences. 405

Results of some trials suggested that COVID-19 convalescent plasma with high-binding 406 antibody titer may be beneficial (Joyner et al., 2021; Libster et al., 2021; Salazar et al., 2021) . In 407 contrast, a meta-analysis of the existing data from ten randomized clinical trials showed that 408 treatment with convalescent plasma was not significantly associated with any benefit for clinical 409 outcome compared to placebo or standard-of-care (Janiaud et al., 2021) . Together, the current 410 evidence from the literature and our findings suggest a more complex, nonlinear relationship 411 between binding and neutralization in plasma than was initially expected and indicate that high 412 binding is not equivalent to potent neutralization. Our work suggests that quantitative antibody 413 neutralization screening is necessary to definitively evaluate the efficacy of convalescent plasma 414 in clinical trials. 415

Numerous laboratory assays measure neutralization of the infection of cells with either the 416 authentic SARS-CoV-2, SARS-CoV-2 containing luciferase reporter genes, replicating VSV-417 SARS-CoV-2 chimeric viruses, or VSV-or lentivirus-based non-replicative pseudoviruses 418

incorporating SARS-CoV-2 spike and reporter genes. Infection is measured by quantifying either 419 the number of infected cells, signal from the reporter gene, the production of viral RNA or 420 infectious virus, or virus-induced CPE (Khoury et al., 2020) . Trials that have included assessing 421 neutralizing titers in convalescent plasma have primarily used BSL3 assays with authentic SARS-422

CoV-2 or BSL2 pseudovirus assays (Anderson et al., 2020; Jackson et al., 2020) . Given the limited 423 availability of BSL3 laboratory space and low throughput, the use of authentic virus screening is 424 not scalable across the many sites seeking to conduct convalescent plasma studies. The RTCA-425 based testing methodology we describe in this study offers several advantages over traditional 426 neutralization assays. These include (1) achieving a high level of accuracy and reproducibility in 427 CPE quantification by implementing an objective and quantitative measurement of cellular 428 impedance in infected cells; (2) allowing for automation and kinetic measurements; (3) reducing 429 hands-on time while providing capacity for medium-to-high throughput testing that includes 430 hundreds of samples per instrument per testing; and (4) testing in BSL2 laboratory settings using 431 chimeric VSV-SARS-CoV-2. The assay could also be adapted for BSL3 testing with authentic 432 viruses, including variants of concern. Therefore, plasma neutralization screening can be 433 conducted immediately in a BSL-3 laboratory after rapid isolation of authentic circulating viruses. 434

This would precede the availability of validated recombinant antigens or chimeric viruses. To 435 increase the efficiency of convalescent plasma screening further, we also developed a sequential 436 RBD binding + neutralization-testing two-step workflow, which has been implemented to select 437 transfusion units in the PassITON convalescent plasma trial (Self et al., 2021) . This study addressed these issues by implementing a potent broadly neutralizing 452 recombinant monoclonal antibody cocktail as a universal standard for neutralizing antibody 453 assessment in our convalescent plasma testing workflow. We chose to incorporate antibodies in 454 the standard with demonstrated protective capacity in animal models. These antibodies are also 455 currently in Phase II efficacy trials for prevention or therapy in humans. Unlike the WHO 456 polyclonal antibody plasma standard collected from humans, this recombinant monoclonal 457 antibody cocktail shows equivalent performance across historical SARS-CoV-2 strains and current 458 variants of concern. It can also be produced and distributed on a massive scale for assay 459 standardization across the globe. 460 A recent report defined minimal SARS-CoV-2 neutralizing titer in recipient plasma 461 sufficient for protection in prophylaxis or therapy studies with passively-transferred polyclonal 462 antibodies in a non-human primate challenge model (McMahan et al., 2021) . Defining a protective 463 titer against COVID-19 in humans is an important next step for designing antibody and vaccine 464 interventions, and quantifying functional antibody levels will require the implementation of 465 calibrated neutralization assays. As SARS-CoV-2 variants of concern arise that may have reduced 466 capacity for neutralization by serum or plasma antibodies from previously infected or vaccinated 467 individuals, rapid and standardized neutralization assays will be essential to assessing the impact 468 of SARS-CoV-2 variants on neutralization titers of convalescent plasma. 469

In summary, our findings have broad implications for standardized testing and the design 470 of antibody-based interventions against COVID-19. 471

Additional studies are needed to compare the performance of RTCA to widely used methods such 474 as pseudovirus neutralization assays. The introduction of the ADM03826 standard sample is the 475 first step of a complex multi-step assay harmonization process. Further studies are needed to ensure 476 that the reported result and interpretation are the same regardless of assay methods and conditions. 477

Because both mAbs in the proposed standard (ADM03826) are RBD-targeting, this performance 478 of the standard will not reflect SARS-CoV-2 neutralization via the S2 domain. While the RTCA 479 array is unlikely to be widely deployable in laboratory settings due to high instrument cost and the (IU) of neutralizing activity. ADM03826 was used as an internal reference to calibrate the activity 616 in serum samples, and the activity of ADM03826 was pre-determined using WHO international 617 anti-SARS-CoV-2 human immunoglobulin standard as in (A-B) . The amount of ADM03826 618 monoclonal antibody with estimated activity of 1,000 IU (14.8 μg/mL) is shown for a comparative 619 purpose (violet bar). Serum samples were analyzed in duplicates from serial two-fold dilutions 620 starting from 1:25, and ADM03826 was analyzed in quadruplicates from serial two-fold dilutions 621 starting from 1 μg/mL. Only 40 samples that revealed equal or greater than 80% virus 622 neutralization at the lowest tested dilution (1:25) from total 76 tested samples are shown. Table. 699  Code -We have no unreported custom computer code or algorithms 700  Other -No "All other items" to report.

We studied 168 participants with an exposure history to SARS-CoV-2 infection that donated their 705 plasma in the United States ( Table S1 ). The studies were approved by the Vanderbilt University 706

Medical Center Institutional Review Board, and samples were collected after written informed consent 707 was obtained by research personnel. Participants were included in the study if they were between 18 708 -80 years old and met US FDA requirements for donation of blood products. Specific to COVID-19 709 convalescent plasma donation, participants must have had a reported history of positive diagnostic 710 SARS-CoV-2 PCR test and free of symptoms for 14 days with a negative PCR test for COVID-19 or 711 28 days without repeat testing. Participants must have satisfied requirements per the apheresis device 712 (e.g., Alyx). Persons with blood type AB were allowed to participate without a positive SARS-CoV-713 2 PCR; however, plasma was only collected if antibody testing was positive. There were no additional 714 exclusion criteria. As the study progressed, participants were asked to rate their COVID-19 symptoms 715 subjectively on a scale of 1 to 10 (1 being mild, 10 being severe), and only participants with a symptom 716 score of 3 or greater were invited to participate in plasma collection. Participants were allowed to 717 donate plasma every 7 days for 4 donations without laboratory monitoring. After the fourth donation, 718 participants required a laboratory assessment of total protein and albumin prior to additional donations 719 to assure safety of the procedure. 720 Wash-B.1.1.28 chimeric viruses, as described previously (Chen et al., 2021c) . B.1.1.7 and B.1.617.2 738 were isolated from infected individuals. Viruses were propagated in Vero E6, Vero CCL81 or Vero-739 TMPRSS2 cells and titrated by plaque assay on Vero E6 or Vero-TMPRSS2 cell culture monolayers 740 as previously described (Case et al., 2020a; Chen et al., 2021c; Jackson et al., 2020) . The generation 741 of a replication-competent vesicular stomatitis virus (VSV) expressing SARS-CoV-2 S protein with a 742 21 amino-acid C-terminal deletion that replaces the VSV G protein (VSV-SARS-CoV-2) was 743 described previously (Case et al., 2020b) . The S protein-expressing VSV virus was propagated in 744 MA104 cell culture monolayers (African green monkey, ATCC CRL-2378.1) as described previously 745 (Case et al., 2020a) . All work with infectious SARS-CoV-2 was performed in Institutional Biosafety 746 Human recombinant mAbs COV2-2196 and CR3022 were described previously (Zost et al., 2020a) . 752 ADM03826 Drug Product was formulated with two human mAbs that were produced based on 753 antibody variable region sequences of two previously described neutralizing human mAbs, COV2-754 2381 and COV2-2130 (Zost et al., 2020a) 

Neutralizing activity of convalescent donor serum against authentic SARS-CoV-2 was determined 789 using PRNT as previously described (Jackson et al., 2020) . Briefly, serum samples were heat- was tested in two independent assays performed at different times. Fractional neutralization from 802 duplicate testing was plotted as a function of log2 serum dilution, and the dose-response relationship 803 was estimated using five-parameter logistic regression analysis using Prism software (version 9.1.2; 804 GraphPad). PRNT50 and PRNT80 titer values, expressed as the reciprocal of the highest serum dilution 805 reducing virus infectivity by 50% or 80%, respectively, were interpolated from regression curves. If a 806 serum titration failed to generate 50% inhibition within the range of dilutions tested a titer value of 807 one-half of the lowest serum dilution (highest serum concentration) tested was assigned to it. 808 809

To determine neutralizing activity of purified recombinant IgG or human serum, we used a real-time 811 cell analysis (RTCA) assay on an xCELLigence RTCA MP Analyzer (Agilent Technologies) that 812 measures virus-induced cytopathic effect (CPE) (Gilchuk et al., 2020a; Suryadevara et al., 2021; Zost 813 et al., 2020b) . Briefly, 50 μL of cell culture medium (DMEM supplemented with 2% FBS, 10 mM 814 HEPES (pH 7.3), 1 mM sodium pyruvate, and 100 U/mL of penicillin and streptomycin) was added 815 to each well of a 96-well E-plate using a ViaFlo384 liquid handler (Integra Biosciences) to obtain 816 background reading. A suspension of 18,000 Vero cells in 50 μL of cell culture medium was seeded 817 in each well, and the plate was placed on the analyzer. Measurements were taken automatically every 818 15 min, and the sensograms were visualized using RTCA software version 2.1.0 (Agilent 819 Technologies). VSV-SARS-CoV-2 (0.01 MOI, ~120 PFU per well) was mixed 1:1 with a respective 820 dilution of human serum sample or monoclonal antibody in a total volume of 100 μL using cell culture 821 medium as a diluent and incubated for 1 h at 37°C in 5% CO2. 

Serum testing was performed in small batches and based on plasma availability collected from donors, 846 and the thresholds for RBD binding (≥8,000 EU/mL) and neutralizing (NT50≥ 50) activities in our 847 two-step screening approach were selected empirically from the limited data available. We chose 848 NT50≥ 50 as a cut-off for the neutralization threshold. This is two-fold over the limit of the detection 849 of RTCA assay (1:25 was the first serum dilution tested) and the threshold allowed a sufficient fraction 850 of convalescent plasma samples to be used for transfusions (17 of 76 or ~22% of the original units 851 would have met this criterion). The binding threshold was chosen to incorporate all neutralizers with 852 NT50≥ 50 in the initial studies with 76 samples. Sensitivity was estimated as the proportion of samples 853 above binding threshold (≥8,000 EU/mL) that are positive for neutralizing activity (NT50≥ 50), and 854 specificity was estimated as the proportion of samples below binding threshold (<8,000 EU/mL) that 855 are negative for neutralizing activity (NT50< 50). 856

The assay was performed as described previously (Chen et al., 2021c) . Briefly, serial dilutions of 859 mAbs or serum were incubated with 10 2 focus-forming units of different strains or variants of SARS-860

CoV-2 for 1 h at 37°C. Antibody-virus complexes were added to Vero-TMPRSS2 cell monolayers in 861 96-well plates and incubated at 37°C for 1 h. Subsequently, cells were overlaid with 1% (w/v) 862 methylcellulose in MEM supplemented with 2% FBS. Plates were collected 30 h later by removing 863 overlays and fixed with 4% paraformaldehyde in PBS for 20 min at room temperature. Plates were 864 washed and sequentially incubated with an oligoclonal pool of SARS2-2, SARS2-11, SARS2-16, 865 SARS2-31, SARS2-38, SARS2-57 and SARS2-71 mouse anti-S antibodies (Liu et al., 2021; 866 VanBlargan et al., 2021) and HRP-conjugated goat anti-mouse IgG (Sigma-Aldrich) in PBS 867 supplemented with 0.1% saponin and 0.1% bovine serum albumin. SARS-CoV-2-infected cell foci 868 were visualized using TrueBlue peroxidase substrate (KPL) and quantitated on an ImmunoSpot 869 microanalyzer (Cellular Technologies). 870 

(2) (3) (4) (5) (6)

(8) (9) (10) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41 

WHO International Standard for anti-SARS-CoV-2 human 756 immunoglobulin was purchased from NIBSC. Plasma and serum samples

Quantification of binding IgG against the receptor-binding domain (RBD) of SARS-CoV-2 was 762 performed on donor sera using a liquid bead-array assay as previously described

Briefly, recombinant RBD protein was produced and purified as described previously

96-well plates with serially diluted serum samples and a SARS-CoV spike-reactive 766 monoclonal antibody CR3022 as a standard. Serum IgG bound to SARS-CoV-2 RBD was

R-Phycoerythrin conjugated F(ab)2 fragment goat anti-human IgG Fc gamma conjugate

Beads were acquired from 96-well plates using a Luminex MagPix Instrument at 769 100 beads per well

Commercial anti-SARS-CoV-2 antibody serological tests

Serum samples were tested using two automated clinical-use methodologies

Two automated research-use 776 methodologies were also utilized: [3] Leinco COVID-19 Trace IgG MICRO-ELISA Kit, a 777 chemiluminescent assay measuring reactivity to immobilized RBD domain of S protein; and [4] 778 temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 910 convalescent plasma donor candidates

Severe acute respiratory syndrome coronavirus 2 914 neutralizing antibody titers in convalescent plasma and recipients in New Mexico: an open 915 treatment study in patients with coronavirus disease 2019

Growth, detection, 918 quantification, and inactivation of SARS-CoV-2

Neutralizing antibody and soluble ACE2 Inhibition of a 922 replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2

Convergent antibody responses to the SARS-927

CoV-2 spike protein in convalescent and vaccinated individuals. bioRxiv

In vivo monoclonal antibody efficacy against SARS-CoV-932 2 variant strains

Resistance of SARS-CoV-2 variants to neutralization by 936 monoclonal and serum-derived polyclonal antibodies

A neutralizing human antibody binds to the N-terminal domain of the Spike 940 protein of SARS-CoV-2

Dynamics of SARS-CoV-2 neutralising antibody responses and 944 duration of immunity: a longitudinal study

Persistence and Evolution of SARS-CoV-2 in an 947 Immunocompromised Host

Immune correlates of protection by mRNA-1273 immunization 951 against SARS-CoV-2 infection in nonhuman primates. bioRxiv

Association of convalescent plasma treatment with 1004 clinical outcomes in patients with COVID-19: a systematic review and meta-analysis

The neutralizing 1009 antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

Convalescent plasma antibody levels 1014 and the risk of death from Covid-19

SARS-CoV-2 evolution during treatment 1018 of chronic infection

Neutralizing antibody levels are highly 1022 predictive of immune protection from symptomatic SARS-CoV-2 infection

Measuring immunity to SARS-CoV-2 infection: 1027 comparing assays and animal models

Correlates of protection from SARS-CoV-2 infection

Serology assays to manage COVID-19

A longitudinal study of SARS-CoV-2-infected patients 1037 reveals a high correlation between neutralizing antibodies and COVID-19 severity

Early high-titer plasma therapy to prevent 1042 severe Covid-19 in older adults

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Identification of SARS-CoV-2 spike 1050 mutations that attenuate monoclonal and serum antibody neutralization

Harmonization of Zika neutralization assays by using 1055 the WHO International Standard for anti-Zika virus antibody. Npj Vaccines 4

Establishment of the WHO International 1060 standard and reference panel for anti-SARS-CoV-2 antibody

N-terminal domain antigenic mapping reveals a site 1065 of vulnerability for SARS-CoV-2

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive 1069 antibody escape

Correlates of protection against SARS-CoV-2 in rhesus 1073 macaques

Longitudinal serological analysis and neutralizing 1077 antibody levels in coronavirus disease 2019 convalescent patients

Cross-neutralization of SARS-CoV-2 by a human 1081 monoclonal SARS-CoV antibody

Safety and efficacy of the BNT162b2 mRNA 1085 Covid-19 vaccine

SARS-CoV-2 serologic assays in control 1089 and unknown populations demonstrate the necessity of virus neutralization testing

Convergent antibody responses

CoV-2 in convalescent individuals

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection 1098 from disease in a small animal model

Significantly decreased mortality in a large cohort 1102 of coronavirus disease 2019 (COVID-19) patients transfused early with convalescent plasma 1103 containing high-titer anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike 1104 protein IgG

Passive Immunity

Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating 1109 COVID-19 convalescent plasma in hospitalized adults

Neutralizing and protective human 1114 monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Association between SARS-CoV-2 1119 neutralizing antibodies and commercial serological assays

Neutralizing monoclonal antibodies for treatment of COVID-19

Inference of SARS-CoV-2 spike-1126 binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using 1127 commercial enzyme and chemiluminescent immunoassays

A potently neutralizing anti-SARS-CoV-2 antibody inhibits 1132 variants of concern by binding a highly conserved epitope. bioRxiv

Prevalent, protective, and convergent IgG 1137 recognition of SARS-CoV-2 non-RBD spike epitopes

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

TMPRSS2 and TMPRSS4 promote 1145 SARS-CoV-2 infection of human small intestinal enterocytes

Potently neutralizing and protective human antibodies 1150 against SARS-CoV-2

1155 1156 1. A high-throughput approach enabling antibody activity testing in COVID-19 plasma 2. SARS-CoV-2 IgG binding screen coupled with quantitative neutralization testing 3. Neutralization testing is necessary for profiling COVID-19 convalescent plasma 4

promising COVID-19 treatment, another achievement in administration's fight against pandemic. 957Available at: https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-958authorization-convalescent-plasma-potential-promising-covid-19-treatment (accessed 10 June 959 2021 Gilchuk, P., Bombardi, R.G., Erasmus, J.H., Tan, Q., Nargi, R., Soto, C., Abbink, P., Suscovich, 976T